@article{MTMT:34793269,
	title = {Hozzátartozókat Támogató Klub az Országos Onkológiai Intézetben},
	url = {https://m2.mtmt.hu/api/publication/34793269},
	author = {Nádas, Orsolya Erzsébet and Fügei, Éva and Kordáné Horváth, Orsolya},
	journal-iso = {ORVOSI KÖNYVTÁRAK},
	journal = {ORVOSI KÖNYVTÁRAK},
	volume = {64},
	unique-id = {34793269},
	issn = {2061-036X},
	year = {2024},
	eissn = {2061-0378},
	pages = {41-41},
	orcid-numbers = {Kordáné Horváth, Orsolya/0000-0002-5456-7200}
}

@article{MTMT:34756803,
	title = {A korszerű szupportív ellátás és az integrált korai palliatív gondozás jelentősége és fontosabb területei agydaganatos betegek kezelése során},
	url = {https://m2.mtmt.hu/api/publication/34756803},
	author = {Kordáné Horváth, Orsolya and Kovács, Péter},
	journal-iso = {MAGYAR ONKOLÓGIA},
	journal = {MAGYAR ONKOLÓGIA},
	volume = {68},
	unique-id = {34756803},
	issn = {0025-0244},
	year = {2024},
	eissn = {2060-0399},
	pages = {77-85},
	orcid-numbers = {Kordáné Horváth, Orsolya/0000-0002-5456-7200; Kovács, Péter/0009-0003-6352-2113}
}

@misc{MTMT:34685827,
	title = {Daganatos betegek palliatív kezelése},
	url = {https://m2.mtmt.hu/api/publication/34685827},
	author = {Kordáné Horváth, Orsolya},
	unique-id = {34685827},
	year = {2024},
	orcid-numbers = {Kordáné Horváth, Orsolya/0000-0002-5456-7200}
}

@article{MTMT:34343034,
	title = {Az onkopszichológiai ellátás hazai gyakorlata: keretek, irányelvek, lehetőségek},
	url = {https://m2.mtmt.hu/api/publication/34343034},
	author = {Kovács, Péter and Kordáné Horváth, Orsolya},
	journal-iso = {MAGYAR ONKOLÓGIA},
	journal = {MAGYAR ONKOLÓGIA},
	volume = {67},
	unique-id = {34343034},
	issn = {0025-0244},
	year = {2023},
	eissn = {2060-0399},
	pages = {39-39},
	orcid-numbers = {Kordáné Horváth, Orsolya/0000-0002-5456-7200}
}

@article{MTMT:34199654,
	title = {Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study},
	url = {https://m2.mtmt.hu/api/publication/34199654},
	author = {Váradi, Melinda and Kordáné Horváth, Orsolya and Módos, Orsolya and Fazekas, Tamás and Grunewald, Camilla M and Niegisch, Günter and Krafft, Ulrich and Grünwald, Viktor and Hadaschik, Boris and Oláh, Csilla and Maráz, Anikó and Furka, Andrea and Szűcs, Miklós and Nyirády, Péter and Szarvas, Tibor},
	doi = {10.1038/s41598-023-44103-9},
	journal-iso = {SCI REP},
	journal = {SCIENTIFIC REPORTS},
	volume = {13},
	unique-id = {34199654},
	issn = {2045-2322},
	abstract = {Clinical trials revealed significant antitumor activity for immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC). Due to their strict eligibility criteria, clinical trials include selected patient cohorts, and thus do not necessarily represent real-world population outcomes. In this multicentric, retrospective study, we investigated real-world data to assess the effectiveness of pembrolizumab and atezolizumab and to evaluate the prognostic value of routinely available clinicopathological and laboratory parameters. Clinical and follow-up data from mUC patients who received ICIs (01/2017-12/2021) were evaluated. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and duration of response (DOR) were used as endpoints. Patients' (n = 210, n = 76 atezolizumab and 134 pembrolizumab) median OS and PFS were 13.6 and 5.9 months, respectively. Impaired ECOG-PS, the presence of visceral, liver or bone metastases, and hemoglobin levels were independently associated with poor OS and DCR. Furthermore, Bellmunt risk factors and the enhanced Bellmunt-CRP score were shown to be prognostic for OS, PFS and DCR. In conclusion, ICIs are effective treatments for a broad range of mUC patients. Our results confirmed the prognostic value of numerous risk factors and showed that Bellmunt risk scores can further be improved when adding CRP to the model.},
	year = {2023},
	eissn = {2045-2322},
	orcid-numbers = {Váradi, Melinda/0000-0001-7733-0831; Kordáné Horváth, Orsolya/0000-0002-5456-7200; Módos, Orsolya/0000-0001-7138-8565; Maráz, Anikó/0000-0002-2018-8413; Szűcs, Miklós/0000-0003-3576-8637; Nyirády, Péter/0000-0002-7037-4919; Szarvas, Tibor/0000-0002-6321-0799}
}

@misc{MTMT:34126580,
	title = {Szunitinib kezelés aktualitásai, betegedukáció jelentősége a mellékhatások menedzselésében},
	url = {https://m2.mtmt.hu/api/publication/34126580},
	author = {Kordáné Horváth, Orsolya},
	unique-id = {34126580},
	year = {2023},
	orcid-numbers = {Kordáné Horváth, Orsolya/0000-0002-5456-7200}
}

@misc{MTMT:33653457,
	title = {Daganatos betegek palliatív kezelése},
	url = {https://m2.mtmt.hu/api/publication/33653457},
	author = {Kordáné Horváth, Orsolya},
	unique-id = {33653457},
	year = {2023},
	orcid-numbers = {Kordáné Horváth, Orsolya/0000-0002-5456-7200}
}

@article{MTMT:33198986,
	title = {High Pretreatment Serum PD-L1 Levels Are Associated with Muscle Invasion and Shorter Survival in Upper Tract Urothelial Carcinoma},
	url = {https://m2.mtmt.hu/api/publication/33198986},
	author = {Széles, Ádám Dániel and Kovács, Petra Terézia and Pásztor-Csizmarik, Anita and Váradi, Melinda and Riesz, Péter and Fazekas, Tamás and Váncsa, Szilárd and Hegyi, Péter and Oláh, Csilla and Tschirdewahn, Stephan and Darr, Christopher and Krafft, Ulrich and Grünwald, Viktor and Hadaschik, Boris and Kordáné Horváth, Orsolya and Nyirády, Péter and Szarvas, Tibor},
	doi = {10.3390/biomedicines10102560},
	journal-iso = {BIOMEDICINES},
	journal = {BIOMEDICINES},
	volume = {10},
	unique-id = {33198986},
	abstract = {Programmed death ligand-1 (PD-L1) is an immune checkpoint molecule and a widely used therapeutic target in urothelial cancer. Its circulating, soluble levels (sPD-L1) were recently suggested to be associated with the presence and prognosis of various malignancies but have not yet been investigated in upper tract urothelial carcinoma (UTUC). In this study, we assessed sPD-L1 levels in 97 prospectively collected serum samples from 61 UTUC patients who underwent radical nephroureterectomy (RNU), chemotherapy (CTX), or immune checkpoint inhibitor (ICI) therapy. In addition to pretreatment samples, postoperative and on-treatment sPD-L1 levels were determined in some patients by using ELISA. In the RNU group, elevated preoperative sPD-L1 was associated with a higher tumor grade (p = 0.019), stage (p < 0.001) and the presence of metastasis (p = 0.002). High sPD-L1 levels were significantly associated with worse survival in both the RNU and CTX cohorts. sPD-L1 levels were significantly elevated in postoperative samples (p = 0.011), while they remained unchanged during CTX. Interestingly, ICI treatment caused a strong, 25-fold increase in sPD-L1 (p < 0.001). Our results suggest that elevated preoperative sPD-L1 level is a predictor of higher pathological tumor stage and worse survival in UTUC, which therefore may help to optimize therapeutic decision-making. The observed characteristic sPD-L1 flare during immune checkpoint inhibitor therapy may have clinical significance.},
	keywords = {CHEMOTHERAPY; Prognosis; biomarker; sPD-L1; Immune checkpoint inhibitor therapy; upper tract urothelial carcinoma; Radical nephroureterectomy; UTUC; soluble programmed death ligand-1},
	year = {2022},
	eissn = {2227-9059},
	orcid-numbers = {Váradi, Melinda/0000-0001-7733-0831; Riesz, Péter/0000-0001-5304-5841; Váncsa, Szilárd/0000-0002-9347-8163; Hegyi, Péter/0000-0003-0399-7259; Kordáné Horváth, Orsolya/0000-0002-5456-7200; Nyirády, Péter/0000-0002-7037-4919; Szarvas, Tibor/0000-0002-6321-0799}
}

@article{MTMT:33094240,
	title = {A hospice-palliatív ellátás hatékony integrálása a hazai onkológiai és családorvosi gyakorlatba},
	url = {https://m2.mtmt.hu/api/publication/33094240},
	author = {Kordáné Horváth, Orsolya and Rácz, Katalin and Jakus, Nikoletta and Kegye, Adrienne and Hegedűs, Katalin},
	doi = {10.1556/650.2022.32561},
	journal-iso = {ORV HETIL},
	journal = {ORVOSI HETILAP},
	volume = {163},
	unique-id = {33094240},
	issn = {0030-6002},
	year = {2022},
	eissn = {1788-6120},
	pages = {1520-1527},
	orcid-numbers = {Kordáné Horváth, Orsolya/0000-0002-5456-7200; Kegye, Adrienne/0000-0001-8838-830X; Hegedűs, Katalin/0000-0001-9463-8854}
}

@article{MTMT:32541121,
	title = {A komplex onkopszichológiai ellátás gyakorlata az Országos Onkológiai Intézetben},
	url = {https://m2.mtmt.hu/api/publication/32541121},
	author = {Kovács, Péter and Kordáné Horváth, Orsolya},
	journal-iso = {MAGYAR ONKOLÓGIA},
	journal = {MAGYAR ONKOLÓGIA},
	volume = {65},
	unique-id = {32541121},
	issn = {0025-0244},
	year = {2021},
	eissn = {2060-0399},
	pages = {34-34},
	orcid-numbers = {Kordáné Horváth, Orsolya/0000-0002-5456-7200}
}